Tolvaptan, a selective oral vasopressin V₂-receptor antagonist, for hyponatremia

Keyphrases

• Aquaresis 10%
• Area under the Curve 10%
• Change from Baseline 10%
• Chronic Hyponatremia 20%
• Cirrhosis 10%
• Days of Therapy 10%
• Dry Mouth 10%
• Electrolyte-free Water 10%
• Euvolemic Hyponatremia 20%
• General Health 10%
• Health Surveys 10%
• Hypervolemic Hyponatremia 20%
• Hyponatremia 100%
• Medical Outcomes Study 10%
• Mental Component 10%
• Mortality Prediction 10%
• Orally Active 10%
• Patients with Chronic Heart Failure 10%
• Placebo 10%
• Placebo Groups 10%
• Randomized Placebo-controlled Trial 10%
• Serum Sodium 50%
• Tolvaptan 100%
• Urination 10%
• Vasopressin V2 Receptor Antagonist 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Congestive Heart Failure 10%
• Health Survey 10%
• Hyponatremia 100%
• Liver Cirrhosis 10%
• Placebo 30%
• Receptor Antagonist 100%
• Side Effect 10%
• Table Salt 20%
• Tolvaptan 100%
• Vasopressin V2 Receptor 100%
• Xerostomia 10%